


Stock Spotlight Report

Issue #19 -- December 5th, 2021

Innovative Genetics
Therapy Research

NTLA

Intellia Therapeutics, Inc.



TIMINGRESEARCH.COM

Important: This document is intended for informational and entertainment purposes only, please read the full disclaimer on the last page of this document.

Bonus! Before you read the full report, check out these other partner offers and educational opportunities...

- Don't risk your capital! [Trade with other people's money](#)

Be sure to check out other recent issues of this report, you can download all of the past issues at the [Stock Spotlight Reports Download Page on TimingResearch.com](#).

Other Recent Issue Titles:

- Issue #18 (11/28/21): Logistics, Cybersecurity, Financing In One Strong Company (PLUS)
- Issue #17 (11/21/21): Machine Learning For Solar Industry (ARRY)
- Issue #16 (11/14/21): Established 3D Printer With Massive Potential (DDD)

Read on to learn more about NTLA...

TIMINGRESEARCH.COM

STOCK SPOTLIGHT REPORT - December 5th, 2021: This new weekly report series will provide info on one exciting stock that investors may want to assess for their portfolio. This is a BETA TEST and will further develop it over time. Please send any feedback [HERE](#).

You are reading Issue #019: Innovative Genetics Therapy Research (NTLA)

Download ALL past Stock Spotlight Reports [HERE](#).

NASDAQ: NTLA Intellia Therapeutics, Inc.

Intellia Therapeutics is a gene editing company developing treatments using the CRISPR/Cas9 system. This technology is in very early stages but has massive long-term potential for use in treating a variety of conditions.

NTLA's market cap is currently around \$7.5 Billion, with an average daily share volume of about 700,000. The company currently pays no dividend. The stock is up about 150% over the last year (as compared to about 22% for S&P500).

NTLA may be a stock to consider for long-term investment in genetics technology.

Read on for charts, more info about NTLA, similar companies, and other relevant info.

1-Year Daily NTLA chart generated by [TradingView](#):

timingresearch published on TradingView.com, Dec 05, 2021 07:36 UTC-5



TradingView

5-Year Weekly NTLA chart generated by [TradingView](#):

timingresearch published on TradingView.com, Dec 05, 2021 07:37 UTC-5



TradingView

MORE INFO

NTLA Website: intelliatx.com ([detailed investor brochure PDF](#))

Sector(s): Healthcare

Industry: Biotechnology

Location: Cambridge, MA, USA

Founded: 2014 / IPO: 2016

Prominent ETFs that hold NTLA:

- ARKK - ARK Innovation ETF
- ARKG - ARK Genomic Revolution ETF
- GNOM - Global X Genomics & Biotechnology ETF
- BIB - ProShares Ultra NASDAQ Biotechnology
- IWM - iShares Russell 2000 ETF

Competitors and/or Related Companies:

- EDIT - Editas Medicine, Inc.
- CRSP - CRISPR Therapeutics AG
- BEAM - Beam Therapeutics Inc.

Related Info:

- Video: [Intellia Therapeutics \(NTLA\) Posts Ground-Breaking Genomic Results | What You Need To Know](#)
- Video: [Intellia CEO on Crispr gene-editing treatment, secondary offering](#)

TIMINGRESEARCH INFO

Download ALL past Stock Spotlight Reports [HERE](#).

Related TimingResearch Episodes:

- NTLA (12/05/2021): [Analyze Your Trade Episode #177 \(John Nyaradi\)](#)
- CRSP (07/27/2021): [Analyze Your Trade Episode #166 \(John Nyaradi\)](#)

Join Us For These Future Events:

- [Crowd Forecast News](#) - Since August 2014, the weekly CFN show has featured a discussion with 2-5 trading experts about where they think the S&P500 is headed, what they are watching for in the markets currently, and their best current trade ideas. Submit your requests for topics for the next episode [here](#).
- [Analyze Your Trade](#) - Created in partnership with [FollowMeTrades.com](#) in August 2017, each Tuesday at 4PM ET (plus occasional special bonus episodes), the AYT show involves surveying the audience for the top symbols that they want our guest expert of the week to analyze live. Submit your symbol requests for the next episode [here](#).

Mark your calendar for the following [Synergy Trader events](#) - This series is a partnership created with [TradeOutLoud.com](#) in August 2019; for this educational series we bring together some of the world's top traders to share their secrets, tips, tricks, and tactics:

2022 Schedule:

- March 8th-10th (3 days): 4th Annual Women Teach Trading And Investing
- April 19th-21st (3 days): Tech Wizards
- May 25th-26th (2 days): Psychology, Discipline, and Time Management
- June 21st-23rd (3 days): Options/Forex/Futures
- July 13th-14th (2 days): Investing and Long-Term Trading
- September 7th-8th (2 days): VIX and News Event Trading
- October 5th-6th (2 days): Commodities & Cannabis
- November 15th-17th (3 days): Friendsgiving (open topic)

STOCK SPOTLIGHT REPORT HISTORY

- This report has been published every Sunday since 08/01/21. The stocks profiled for this report are mainly chosen for a 5+ year investment time horizon, but if you want to see their change since being profiled in this report, the results are available below.
- “Gain” column below is calculated from the Open price of the stock on the first trading day after the report is published until the Close price of the most recent trading day.
- “Gain” does NOT include dividends reinvestment for the companies that pay dividends.
- “Benchmark” is VT (Vanguard Total World Stock Index Fund ETF).

SSR Stocks Average Gain: -1.1%

Benchmark Average Gain: -1.9%

SSR Stocks with higher gain than the Benchmark: 50.0%

ISSUE	DATE	SYMBOL	-1.1% GAIN	-1.9% BENCHMARK	50.0% WIN?
1	08/01/21	BHVN	-17.8%	-1.0%	0
2	08/08/21	SCCO	-10.2%	-1.4%	0
3	08/15/21	LTHM	11.6%	-1.5%	1
4	08/22/21	FTNT	1.7%	0.6%	1
5	08/29/21	CUBE	2.9%	-2.5%	1
6	09/05/21	KEYS	10.0%	-3.6%	1
7	09/12/21	PFLT	0.2%	-2.8%	1
8	09/19/21	ENPH	40.4%	0.9%	1
9	09/26/21	GMED	-22.4%	-0.9%	0
10	10/03/21	AQUA	20.5%	1.4%	1
11	10/10/21	TRUP	32.0%	0.6%	1
12	10/17/21	DDOG	6.0%	-1.1%	1
13	10/24/21	FCX	-4.4%	-2.8%	0
14	10/31/21	FUV	-23.8%	-3.4%	0
15	11/07/21	MIME	-7.1%	-5.0%	0
16	11/14/21	DDD	-17.2%	-5.0%	0
17	11/21/21	ARRY	-32.6%	-4.3%	0
18	11/28/21	PLUS	-9.4%	-2.1%	0

DISCLAIMER - PLEASE READ

TimingResearch owners, guests, affiliates, and associates are real traders and investors and may hold the equities discussed in this report directly or indirectly through ETFs or other funds.

This report is for information and entertainment purposes only; trading and investing is extremely risky. We've made every reasonable attempt to ensure that the above information is accurate at the time of publication, but please do your own research. The reader bears sole responsibility for their trading and investing decisions. Please consult a qualified financial advisor for help with financial decisions.

TimingResearch may generate revenue from any link on the website, emails, reports, or any other content.

Statement Of Disclaimer: U.S. Government Required Disclaimer - Commodity Futures Trading Commission. Futures, option, forex and stock trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This website/email is neither a solicitation nor an offer to Buy/Sell futures, options, forex or stocks. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - Hypothetical or simulated performance results have certain limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity. Simulated trading programs in general are also subject to the fact that they are designed with the benefit of hindsight. No representation is being made that any account will or is likely to achieve profit or losses similar to those shown.